
FSH & LH
Follicle-Stimulating Hormone & Luteinising Hormone
What it is
Follicle-stimulating hormone (FSH) and luteinising hormone (LH) are gonadotropins — glycoprotein hormones produced by gonadotroph cells of the anterior pituitary in response to pulsatile gonadotropin-releasing hormone (GnRH) from the hypothalamus. In females, FSH stimulates the growth and maturation of ovarian follicles; LH triggers ovulation (the LH surge) and stimulates the corpus luteum to produce progesterone. In males, FSH acts on Sertoli cells to support spermatogenesis, while LH acts on Leydig cells to stimulate testosterone production. Both hormones operate within a negative feedback loop: rising sex hormones (testosterone, oestradiol, progesterone) suppress FSH and LH secretion; falling sex hormones allow FSH and LH to rise. Inhibin B (produced by Sertoli cells in males and granulosa cells in females) provides additional FSH-specific suppression. This feedback architecture means that FSH and LH levels not only reflect gonadotropin production, but also encode the functional status of the gonads — making them indispensable for localising the site of hormonal dysfunction.
Why we measure it
FSH and LH are the diagnostic bridge between the pituitary and the gonads. In females, rising FSH is the earliest measurable signal of declining ovarian reserve — it rises as the diminishing follicle pool produces less inhibin B and oestradiol, causing the pituitary to increase FSH output in an attempt to recruit remaining follicles. Early-day FSH above 10 IU/L signals significantly reduced ovarian reserve and reduced fertility, even before AMH falls below the typical clinical threshold. In males, the FSH and LH pattern distinguishes primary hypogonadism (testicular failure — high LH and FSH with low testosterone, as the pituitary compensates) from secondary hypogonadism (pituitary or hypothalamic dysfunction — low LH and FSH with low testosterone, confirming the fault is upstream). This distinction fundamentally changes clinical management: primary hypogonadism requires testosterone replacement; secondary may respond to gonadotropin stimulation or treatment of the underlying pituitary pathology. In females with polycystic ovary syndrome (PCOS), an elevated LH:FSH ratio (typically > 2:1) in the early follicular phase is a classical finding reflecting disordered GnRH pulsatility.
Why every 6 months
In premenopausal females, FSH and LH vary significantly across the menstrual cycle — FSH peaks in the early follicular phase and at ovulation; LH surges dramatically at ovulation (triggering egg release). For consistent interpretation, FSH should ideally be measured on days 2–5 of the menstrual cycle (early follicular phase). LH measured at any other time may reflect the mid-cycle surge rather than the basal pituitary output. In males, gonadotropins show less intra-individual variability and can be measured at the same morning draw as testosterone. The six-month interval tracks meaningful changes — the progressive FSH rise of perimenopause, the gonadotropin response to treatment, or the gradual LH suppression that accompanies rising BMI and leptin.
What movement means
Reference ranges vary by sex, age, and menstrual cycle phase. Ranges below are approximate; laboratory-specific values should be consulted. FSH and LH are reported in IU/L (international units per litre).
Normal — Early Follicular (Female)
FSH: 3 – 10 IU/L · LH: 2 – 15 IU/L
Normal basal pituitary gonadotropin output in the early follicular phase (days 2–5). FSH within this range suggests adequate ovarian reserve for the individual's age.
Standard laboratory reference ranges — vary by assay method and cycle day
Elevated FSH — Female
FSH > 10 IU/L (early follicular)
Indicates reduced ovarian reserve or transition toward menopause. FSH > 10 IU/L in women under 40 warrants investigation for premature ovarian insufficiency. FSH > 25–40 IU/L with low oestradiol indicates established menopause.
NICE Menopause Guideline NG23, 2015 — updated 2019
Normal — Male
FSH: 1.5 – 12.4 IU/L · LH: 1.7 – 8.6 IU/L
Normal reference range for adult males. High FSH with low testosterone indicates primary testicular failure (Sertoli cell dysfunction, spermatogenesis impairment). Low LH with low testosterone indicates secondary hypogonadism.
Standard laboratory reference ranges — vary by assay method
References
- 1.
Speroff L, Fritz MA. “Clinical Gynecologic Endocrinology and Infertility (8th edition).” Lippincott Williams & Wilkins. 2011.
- 2.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. “A Systematic Review of Tests Predicting Ovarian Reserve and IVF Outcome.” Human Reproduction Update. 2006.
- 3.
Bhasin S, Brito JP, Cunningham GR, et al.. “Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline.” Journal of Clinical Endocrinology & Metabolism. 2018.
- 4.
Azziz R, Carmina E, Dewailly D, et al.. “The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report.” Fertility and Sterility. 2009.